An Assessment of Potential Drug-Drug Interactions in

Hypertensive Patients in a Tertiary Care Hospital by Praveen, M
AN ASSESSMENT OF POTENTIAL DRUG-DRUG INTERACTIONS IN 
HYPERTENSIVE PATIENTS IN A TERTIARY CARE HOSPITAL 
 
A Dissertation submitted to 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY,  
CHENNAI- 600 032 
 
In partial fulfilment of the award of the degree of 
MASTER OF PHARMACY 
IN 
Branch - VII – PHARMACY PRACTICE 
 
Submitted by 
Name: Mr. PRAVEEN M 
REG.No. 261640208 
 
Under the Guidance of 
Mr. R. Kameswaran, M.Pharm., (Ph.D), 
DEPARTMENT OF PHARMACY PRACTICE 
 
 
 
 
 
 
J.K.K. NATTRAJA COLLEGE OF PHARMACY 
KUMARAPALAYAM – 638183 
TAMILNADU. 
OCTOBER – 2018 
 
 
AN ASSESSMENT OF POTENTIAL DRUG-DRUG INTERACTIONS 
IN HYPERTENSIVE PATIENTS IN A TERTIARY CARE HOSPITAL  
A Dissertation submitted to 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY,  
CHENNAI - 600 032 
In partial fulfilment of the award of the degree of 
MASTER OF PHARMACY 
IN 
Branch - VII – PHARMACY PRACTICE 
 
Submitted by 
Name: Mr. PRAVEEN M 
REG.No. 261640208 
 
Under the Guidance of 
Mr. R. Kameswaran, M.Pharm., (Ph.D)., 
DEPARTMENT OF PHARMACY PRACTICE 
 
 
 
J.K.K. NATTRAJA COLLEGE OF PHARMACY 
KUMARAPALAYAM – 638183 
TAMILNADU. 
OCTOBER – 2018 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERTIFICATES 
  
 
 
 
This  is  to  certify  that  the  dissertation  work  entitled  “AN 
ASSESSMENT OF POTENTIAL DRUG-DRUG INTERACTIONS IN 
HYPERTENSIVE PATIENTS IN A TERTIARY CARE HOSPITAL”, 
submitted by  the  student  bearing  Reg.  No: 261640208 to “The 
Tamil Nadu  Dr. M.G.R. Medical  University – Chennai”,  in  partial  
fulfilment  for  the  award  of  Degree  of Master  of  Pharmacy  in  
Pharmacy practice was  evaluated  by  us  during  the examination held 
on……………..………. 
 
 
 
 
 
 
 
 
Internal Examiner                 External Examiner 
        
 
 
 
 
 
 
 
 
EVALUATION CERTIFICATE 
 CERTIFICATE 
 
 
 
This is to certify that the work embodied in this dissertation 
entitled “AN ASSESSMENT OF POTENTIAL DRUG-DRUG 
INTERACTIONS IN HYPERTENSIVE PATIENTS IN A TERTIARY CARE 
HOSPITAL”, submitted to “The Tamil Nadu Dr. M.G.R. Medical 
University - Chennai”, in partial fulfilment and requirement of 
university rules and regulation for the award of Degree of Master of 
Pharmacy in Pharmacy practice, is a bonafide work carried out by the 
student bearing Reg.No. 261640208 during the academic year 2017-2018, 
under my guidance and direct  supervision in the Department of 
Pharmacy practice, J.K.K. Nattraja College of Pharmacy, 
Kumarapalayam. 
 
Mr. R. Kameswaran, M.Pharm., (Ph.D)., 
Guide 
 
 
Dr.N.Venkateswaramurthy, M.Pharm., Ph.D., 
HOD 
 
 
Dr.R.Sambathkumar, M.Pharm., Ph.D., 
Principal 
 
 CERTIFICATE 
 
 
 
 
This is to certify that the work embodied in this dissertation entitled 
“AN ASSESSMENT OF POTENTIAL DRUG-DRUG INTERACTIONS 
IN HYPERTENSIVE PATIENTS IN A TERTIARY CARE 
HOSPITAL”, submitted to “The Tamil Nadu Dr. M.G.R. Medical 
University - Chennai”, in partial fulfilment and requirement of 
university rules and regulation for the award of Degree of Master of 
Pharmacy in Pharmacy practice, is a bonafide work carried out by 
the student bearing Reg.No. 261640208 during the academic year 
2017-2018, under the guidance and supervision of Mr. R. Kameswaran, 
M.Pharm., (Ph.D).,  Assistant Professor, Department of Pharmacy Practice, J.K.K. 
Nattraja College of Pharmacy, Kumarapalayam. 
 
 
 
Place: Kumarapalayam  
Date:  
 
   
Dr. R. SambathKumar, M.Pharm., Ph.D., 
Principal, 
J.K.K. Nattraja College of Pharmarcy, 
Kumarapalayam – 638 183,  
Tamil Nadu 
 
CERTIFICATE 
 
 
  
 
This is to certify that the work embodied in this dissertation entitled 
“AN ASSESSMENT OF POTENTIAL DRUG-DRUG INTERACTIONS IN 
HYPERTENSIVE PATIENTS IN A TERTIARY CARE HOSPITAL”, 
submitted to “The Tamil Nadu Dr. M.G.R. Medical University - 
Chennai”, in partial fulfilment and requirement of university rules and 
regulation for the award of Degree of Master of Pharmacy in Pharmacy 
practice, is a bonafide work carried out by the student bearing Reg.No. 
261640208 during the academic year 2017-2018, under the guidance and 
supervision of Mr. R. Kameswaran, M.Pharm., (Ph.D).,  Assistant Professor, 
Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, 
Kumarapalayam. 
 
 
 
 
 
 
 
 
 
Place: Kumarapalayam 
Date:  
 
 
 
 
 
Dr. N. Venkateswaramurthy, M.Pharm., Ph.D., 
Professor & Head, 
Department of Pharmacy Practice,  
J.K.K. Nattraja College of Pharmarcy,  
Kumarapalayam – 638 183,  
Tamil Nadu 
 
  
 
 
 
This is to certify that the work embodied in this dissertation entitled 
“AN ASSESSMENT OF POTENTIAL DRUG-DRUG INTERACTIONS IN 
HYPERTENSIVE PATIENTS IN A TERTIARY CARE HOSPITAL”, 
submitted to “The Tamil Nadu Dr. M.G.R. Medical University - Chennai”, 
in partial fulfilment and requirement of university rules and regulation for 
the award of Degree of Master of Pharmacy in Pharmacy practice, is a 
bonafide work carried out by the student bearing Reg.No. 261640208 during 
the academic year 2017-2018, under my guidance and direct  supervision 
in the Department of Pharmacy practice, J.K.K. Nattraja College of 
Pharmacy, Kumarapalayam. 
 
 
 
 
Place: Kumarapalayam    
Date:            
     
    
 
 
 
 
 
CERTIFICATE 
 
Mr. R. Kameswaran, M.Pharm., (PhD)., 
Assistant Professor, 
Department of Pharmacy practice, 
J.K.K. Nattraja College of Pharmacy. 
Kumarapalayam- 638 183. 
 
DECLARATON 
 
I do hereby declared that the dissertation “AN ASSESSMENT OF 
POTENTIAL DRUG-DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS 
IN A TERTIARY CARE HOSPITAL” submitted to “The Tamil Nadu Dr. 
M.G.R Medical University - Chennai”, for the partial fulfilment of the 
degree of  Master of Pharmacy in Pharmacy practice, is a bonafide 
research work has been carried out by me during the academic year 2017-
2018, under the guidance and supervision of Mr. R. Kameswaran, M. 
Pharm., (Ph.D)., Assistant Professor, Department of Pharmacy practice, 
J.K.K. Nattraja College of Pharmacy, Kumarapalayam.  
I further declare that this work is original and this dissertation has 
not been submitted previously for the award of any other degree, diploma, 
associate ship and fellowship or any other similar title. The information 
furnished in this dissertation is genuine to the best of my knowledge.  
 
 
Place: Kumarapalayam     Mr. PRAVEEN M 
Date:                                                         Reg.no. 261640208 
 
 
 Dedicated to Parents,  
Teachers & 
My Family 
  
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
ACKNOWLEDGEMENT 
 I am proud to dedicate my deep sense of gratitude to the founder, 
(Late) Thiru J.K.K. NattarajaChettiar, providing the historical institution to 
study. 
 
 My sincere thanks and respectful regards to our reverent Chairperson 
Smt. N. Sendamaraai, B.Com., and Director Mr. S. OmmSharravana, 
B.Com., LLB., J.K.K. Nattraja Educational Institutions, Kumarapalayam for 
their blessings, encouragement and support at all times. 
 
 It is most pleasant duty to thank for our beloved Principal Dr. R. 
Sambathkumar, M.Pharm., Ph.D., Professor & Head, Department of 
Pharmaceutics, J.K.K. Nattraja College of Pharmacy, Kumarapalayam for 
ensuring all the facilities were made available to me for the smooth running 
of this project and tremendous encouragement at each and every step of this 
dissertation work. Without his critical advice and deep-rooted knowledge, 
this work would not have been a reality. 
 
 Our glorious acknowledgement to our administrative officer Dr. K. 
Sengodan, M.B.B.S., for encouraging using kind and generous manner to 
complete this work. 
 
 My sincere thanks to Dr. N.Venkateswaramurthy, M.Pharm.,  PhD., 
Professor and Head, Department of Pharmacy Practice, Mrs. K. Krishna 
Veni, M.Pharm., Assistant Professor, Mr. R. Kameswaran, M.Pharm, 
Assistant  Professor, Dr. Cindy Jose, Pharm.D., Lecturer, Dr. S.K. Sumitha, 
Pharm.D., Lecturer, and  Dr. Krishna ravi, Pharm.D., Lecturer, Dr. 
MebinAlis, Pharm.D., Department of Pharmacy Practice, for their help 
during my project. 
 
 My sincere thanks to Dr. S. Bhama, M. Pharm., Associate Professor, 
& Head, Department of Pharmaceutics,Mr. R. Kanagasabai, B.Pharm, 
M.Tech., Assistant Professor, Mr. K. Jaganathan, M.Pharm., Assistant 
Professor, Mr. C. Kannan, M.Pharm., Assistant Professor, Dr.V. 
Kamalakannan, M.Pharm., Ph.D., Assistant Professor, and                         
Ms. Elakiya, M.Pharm., Lecturer, Department of pharmaceutics for the in 
valuable help during my project. 
 
 It is my privilege to express deepest sense of gratitude towards                                         
Dr. M. Vijayabaskaran, M.Pharm.,Ph.D., Professor & Head, Department of 
Pharmaceutical chemistry, Mrs. S. Gomathi M.Pharm., Lecturer, Mrs. B. 
Vasuki, M.Pharm., Lecturer and Mrs. P. Devi, M.Pharm.,  Lecturer, Mrs. 
P. Lekha, M.Pharm.,  Lecturer, for their valuable suggestions and 
inspiration. 
 
 My sincere thanks to Dr. V. Sekar, M.Pharm., Ph.D., Professor & 
Head, Department of Analysis, Dr. I. CaolinNimila, M.Pharm., Ph.D., 
Assistant Professor, and Ms. V. Devi, M.Pharm., Lecturer, Mr. D. 
Kamalakannan, M.Pharm., Assistant Professor, Department of 
Pharmaceutical Analysis for their valuable suggestions. 
 
 My sincere thanks to Dr. Senthilraja, M.Pharm., Ph.D., Associate 
Professor and Head, Department of Pharmacognosy, Mrs. Meena Prabha 
M.Pharm., Assistant professor, Department of  Pharmacognosy for their 
valuable suggestions during my project work. 
 
 My sincere thanks to Dr. R. Shanmugasundaram, M.Pharm., 
Ph.D., Vice Principal & HOD, Department of Pharmacology, Mr. V. 
Venkateswaran, M.Pharm., Assistant Professor, Mrs. M.Sudha M.Pharm., 
Assistant Professor, Mrs. R. Elavarasi, M.Pharm., Lecturer, Mrs. M. Baby 
kala, M.Pharm., Lecturer, Department of Pharmacology for their valuable 
suggestions during my project work. 
 
 I greatly acknowledge the help rendered by Mrs. K. Rani, Office 
Superintendent, Mrs. E. Vimala veni, MCA.,M.Phil., Office typist,   Miss.M. 
Venkateswari, M.C.A., typist, Mrs. V. Gandhimathi, M.A., M.L.I.S., 
Librarian, Mrs. S. Jayakala B.A., B.L.I.S., and Asst. Librarian for their co-
operation. I owe my thanks to all the technical and non-technical staff 
members of the institute for their precious assistance and help. 
 
 Last, but nevertheless, I am thankful to my lovable parents and all my 
friends for their co-operation, encouragement and help extended to me 
throughout my project work.  
 
 
           
       
         Mr. PRAVEEN M 
Reg.no.261640208 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
Sl. No. Particulars Page no. 
1. Introduction 1 
2. Literature review 16 
3. Aim and objectives 25 
4. Result and Figures 29 
5 Discussion 45 
6 Conclusion 49 
7 Reference 50 
8 Annexure 56 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ABBREVIATIONS 
 
ABC Adenosine thiophosphate Binding Cassette 
ADME Absorption, Distribution, Metabolism, Excretion 
ADR Adverse Drug Reactions 
ATH Ayub Teaching Hospital 
AUC Area Under Curve 
CYP Cytochrome P 
DDI Drug-Drug Interaction 
GFJ Grapefruit Juice 
GFR Glomerular Filtration Rate 
hMATE Human Multidrug And Toxin Exclusion 
hOCT Human Organic Cation Transporter 
ICU Intensive Care Unit 
IL Interleukin 
JCAHO 
Joint Commission on Accredictation of Healthcare 
Organization 
MAO Monoamine Oxidase 
NICE National Institute of Health and Care Excellence 
NLP National Language Processing 
PGP Poly Glycoprotein 
PPI Proton Pump Inhibitor 
DDIs  Potential Drug-drug Interactions 
 
           LIST OF TABLES 
Sl.No. Title 
1. 
Mechanisms of drug interactions 
2. 
Examples of drug classes containing several narrow 
therapeutic index (object) drugs 
3. 
Important perpetrators of cytochrome P450 drug–drug 
interactions 
4. 
Distribution of drug-drug interactions in hypertensive 
patients 
5. Gender wise distribution of drug- drug interactions 
6. Age wise distribution 
7. Number of hospital stay 
8. Number of prescribed drugs per day 
9. Distribution of co-morbid condition in hypertensive patients  
10. Highest prescribed single antihypertensive drugs 
11. Highest prescribed combination of 2 antihypertensive drugs 
12. Prescribed combination of 3 antihypertensive drugs 
13. Highest potential drug-drug interaction combinations 
14. 
Anticipated effect, M.O.A, Clinical Management for common 
potential drug-drug interactions in hypertensive patients 
15. Types of Prevalence of pDDIs 
16. Classification of Types of PDDIs 
17. Classification of PK Interactions 
18. Classification of PD Interactions 
 
 
 
 
LIST OF FIGURES 
Fig 
No. 
Title 
1. 
Distribution of drug-drug interactions in hypertensive 
patients 
2. Gender wise distribution of drug- drug interactions 
3. Age wise distribution 
4. Number of hospital stay 
5. Number of prescribed drugs per day 
6. 
Distribution of co-morbidities condition in hypertensive 
patients  
7. Prescribed combination of 3 antihypertensive drugs 
8. 
Highest potential drug-drug interaction combinations in 
hypertensive patients 
9. Types of Prevalence of pDDIs 
10. Classification of Types of PDDIs 
11. Classification of Pharmacokinetics interactions 
12. Classification of Pharmacodynamics interactions 
 
An assessment of potential drug-drug interactions in hypertensive patients in a tertiary care 
hospital 
 
Department of Pharmacy Practice                     1          J.K.K. Nattraja College of Pharmacy 
 
1. INTRODUCTION 
Hypertension, also known as high or raised blood pressure, is a global public health 
issue. It contributes to the burden of heart disease, stroke and kidney failure, and premature 
mortality and disability. It disproportionately affects populations in low- and middle-income 
countries where health systems are weak.
1
 Hypertension rarely causes symptoms in the early 
stages and many people go undiagnosed. Those who are diagnosed may not have access to 
treatment and may not be able to successfully control their illness over the long term.
1-3
 
The globally cardiovascular disease accounts for approximately 17 million deaths a 
year, nearly one-third of the total.
4
 Of these, complications of hypertension account for 9.4 
million deaths worldwide every year.
5
 Hypertension is responsible for at least 45% of deaths 
due to heart disease (total ischemic heart disease mortality), and 51% of deaths due to stroke 
(total stroke mortality).
4
 In 2008, worldwide, approximately 40% of adults aged 25 and above 
had been diagnosed with hypertension; the number of people with the condition rose from 
600 million in 1980 to1 billion in 2008.
6
 
The prevalence of hypertension is highest in the African Region at 46% of adults aged 
25 and above, while the lowest prevalence at 35% is found in the Americas. Overall, high-
income countries have a lower prevalence of hypertension- 35% - than other groups at 40%.
7
 
Drug prescription in HT is complex and many factors such as polypharmacy, 
comorbid conditions, pharmacokinetic and pharmacodynamic variability, and noncompliance 
make this group a high risk as far drug safety is concerned.
8-10
 To inform health care 
providers and to provide pragmatic clinical suggestions and recommendations, international, 
regional, and national hypertension guidelines have been developed by expert groups 
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globally. Most major hypertension treatment guidelines currently suggest that clinicians 
should strive to treat adults to a blood pressure target of ≤140/90 mm Hg.3,11 
1.1. DRUG INTERACTION 
A drug interaction is a situation in which a substance (usually another drug) affects 
the activity of a drug when both are administered together. This action can be synergistic 
(when the drug's effect is increased) or antagonistic (when the drug's effect is decreased) or a 
new effect can be produced that neither produces on its own. Typically, interactions between 
drugs come to mind (drug-drug interaction). However, interactions may also exist between 
drugs and foods (drug-food interactions), as well as drugs and medicinal plants or herbs 
(herb-drug interactions). People taking antidepressant drugs such as monoamine oxidase 
inhibitors should not take food containing tyramine as a hypertensive crisis may occur (an 
example of a drug-food interaction). These interactions may occur out of accidental misuse or 
due to lack of knowledge about the active ingredients involved in the relevant substances.
12
  
It is therefore easy to see the importance of these pharmacological interactions in the 
practice of medicine. If a patient is taking two drugs and one of them increases the effect of 
the other it is possible that an overdose may occur. The interaction of the two drugs may also 
increase the risk that side effects will occur. On the other hand, if the action of a drug is 
reduced it may cease to have any therapeutic use because of under-dosage. Notwithstanding 
the above, on occasion, these interactions may be sought in order to obtain an improved 
therapeutic effect.
13
 Examples of this include the use of codeine with paracetamol to increase 
its analgesic effect. Or the combination of a clavulanic acid with amoxicillin in order to 
overcome bacterial resistance to the antibiotic. It should also be remembered that there are 
interactions that, from a theoretical standpoint, may occur but in clinical practice have no 
important repercussions.  
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The pharmaceutical interactions that are of special interest to the practice of medicine 
are primarily those that have negative effects for an organism. The risk that a 
pharmacological interaction will appear increases as a function of the number of drugs 
administered to a patient at the same time.
14
 Over a third (36%) of older adults in the U.S. 
regularly use 5 or more medications or supplements and 15% are potentially at risk for a 
major drug-drug interaction. Both the use of medications and subsequent adverse drug 
interactions have increased significantly between 2005-2011.
15
  
It is possible that an interaction will occur between a drug and another substance 
present in the organism (i.e. foods or alcohol). Or in certain specific situations, a drug may 
even react with itself, such as occurs with dehydration. In other situations, the interaction 
does not involve any effect on the drug. In certain cases, the presence of a drug in an 
individual's blood may affect certain types of laboratory analysis (analytical interference).  
It is also possible for interactions to occur outside an organism before administration 
of the drugs has taken place. This can occur when two drugs are mixed, for example, in a 
saline solution prior to intravenous injection. Some classic examples of this type of 
interaction include that thiopentone and suxamethonium should not be placed in the same 
syringe and the same is true for benzylpenicillin and heparin. These situations will all be 
discussed under the same heading due to their conceptual similarity.  
Drug interactions may be the result of various processes. These processes may include 
alterations in the pharmacokinetics of the drug, such as alterations in the absorption, 
distribution, metabolism, and excretion (ADME) of a drug. Alternatively, drug interactions 
may be the result of the pharmacodynamic properties of the drug, e.g. the co-administration 
of a receptor antagonist and an agonist for the same receptor.
15
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1.2. SYNERGY AND ANTAGONISM 
When the interaction causes an increase in the effects of one or both of the drugs the 
interaction is called a synergistic effect. An "additive synergy" occurs when the final effect is 
equal to the sum of the effects of the two drugs (Although some authors argue that this is not 
true synergy). When the final effect is much greater than the sum of the two effects this is 
called enhanced synergy. This concept is recognized by the majority of authors,
16
 although 
other authors only refer to synergy when there is an enhanced effect. These authors use the 
term "additive effect" for additive synergy and they reserve use of the term "synergistic 
effect" for enhanced synergy.
17
 The opposite effect to synergy is termed antagonism. Two 
drugs are antagonistic when their interaction causes a decrease in the effects of one or both of 
the drugs. 
Both Synergy and antagonism can both occur during different phases of the 
interaction of a drug with an organism, with each effect having a different name. For 
example, when the synergy occurs at a cellular receptor level this is termed agonism, and the 
substances involved are termed, agonists. On the other hand, in the case of antagonism, the 
substances involved are known as inverse agonists. The different responses of a receptor to 
the action of a drug has resulted in a number of classifications, which use terms such as 
"partial agonist", "competitive agonist" etc. These concepts have fundamental applications in 
the pharmacodynamics of these interactions. The proliferation of existing classifications at 
this level, along with the fact that the exact reaction mechanisms for many drugs are not well-
understood means that it is almost impossible to offer a clear classification for these concepts. 
It is even likely that many authors would misapply any given classification.
17
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1.3. UNDERLYING FACTORS 
It is possible to take advantage of positive drug interactions. However, the negative 
interactions are usually of more interest because of their pathological significance and also 
because they are often unexpected and may even go undiagnosed. By studying the conditions 
that favor the appearance of interactions it should be possible to prevent them or at least 
diagnose them in time. The factors or conditions that predispose or favor the appearance of 
interactions include:
16
  
 Old age: factors relating to how human physiology changes with age may affect the 
interaction of drugs. For example, liver metabolism, kidney function, nerve 
transmission or the functioning of bone marrow all decrease with age. In addition, in 
old age, there is a sensory decrease that increases the chances of errors being made in 
the administration of drugs.
18
  
 Polypharmacy: The more drugs a patient takes the more likely it will be that some of 
them will interact.
19
  
 Genetic factors: Genes synthesize enzymes that metabolize drugs. Some races have 
genotypic variations that could decrease or increase the activity of these enzymes. The 
consequence of this would, on occasions, be a greater predisposition towards drug 
interactions and therefore a greater predisposition for adverse effects to occur. This is 
seen in genotype variations in the isozymes of cytochrome P450. 
 Hepatic or renal diseases: The blood concentrations of drugs that are metabolized in 
the liver and/or eliminated by the kidneys may be altered if either of these organs is 
not functioning correctly. If this is the case an increase in blood concentration is 
normally seen.
19
  
 Serious diseases that could worsen if the dose of the medicine is reduced. 
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 Drug-dependent factors:
20
  
o Narrow therapeutic index: Where the difference between the effective dose 
and the toxic dose is small. The drug digoxin is an example of this type of 
drug. 
o Steep dose-response curve: Small changes in the dosage of a drug produce 
large changes in the drug's concentration in the patient's blood plasma. 
o Saturable hepatic metabolism: In addition to dose effects the capacity to 
metabolize the drug is greatly decreased 
1.4. ANALYTICAL INTERFERENCE 
The detection of laboratory parameters is based on physicochemical reactions 
between the substance being measured and reagents designed for this purpose. These 
reactions can be altered by the presence of drugs giving rise to an overestimation or an 
underestimation of the real results. Levels of cholesterol and other blood lipids can be 
overestimated as a consequence of the presence in the blood of some psychotropic drugs. 
These overestimates should not be confused with the action of other drugs that actually 
increase blood cholesterol levels due to an interaction with its metabolism. Most experts 
consider that these are not true interactions, so they will not be dealt with further in this 
discussion.
21
 
These chemical reactions are also known as pharmacological incompatibilities. The 
reactions occur when two or more drugs are mixed outside the body of the organism for the 
purpose of joint administration.
13
 Usually, the interaction is antagonistic and it almost always 
affects both drugs. Examples of these types of interactions include the mixing of penicillins 
and aminoglycosides in the same serum bottle, which causes the formation of an insoluble 
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precipitate, or the mixing of ciprofloxacin with furosemide. The interaction of some drugs 
with the transport medium can also be included here. This means that certain drugs cannot be 
administered in plastic bottles because they bind with the bottle's walls, reducing the drug's 
concentration in solution. 
Many authors do not consider them to be interactions in the strictest sense of the 
word. An example is the database of the General Council of Official Pharmacists Colleges of 
Spain,
22
 that does not include them among the 90,000 registered interactions. 
1.5. TYPES OF DRUG-DRUG INTERACTIONS 
Interactions between drugs may be categorized by the underlying mechanism (see box):  
 Behavioral drug-drug interactions occur when one drug alters the patient's behavior to 
modify compliance with another drug. For example, a depressed patient taking an 
antidepressant may become more compliant with medication as symptoms improve.
23
  
 Pharmaceutic drug-drug interactions occur when the formulation of one drug is 
altered by another before it is administered. For example, precipitation of sodium 
thiopentone and vecuronium within an intravenous giving set.  
 Pharmacokinetic drug-drug interactions occur when one drug changes the systemic 
concentration of another drug, altering ‘how much' and for ‘how long' it is present at 
the site of action. 
 Pharmacodynamic drug-drug interactions occur when interacting drugs have either 
additive effects, in which case the overall effect is increased or opposing effects, in 
which case the overall effect is decreased or even ‘cancelled out'. 
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Table 1: Mechanisms of drug interactions 
 
Behavioral: altered compliance  
Pharmaceutic: outside the body  
Pharmacokinetic: altered concentration  
Bioavailability: absorption or first-pass metabolism 
Clearance: metabolism or excretion of the active drug 
Distribution: cell membrane transport to the site of action  
Pharmacodynamic: altered effect  
Mechanism: molecular signal (e.g. receptor) 
Mode: physiological effect  
 
1.6. PHARMACOKINETIC DRUG-DRUG INTERACTIONS 
Pharmacokinetics is ‘what the body does to the drug’. These interactions occur when one 
drug (the perpetrator) alters the concentration of another drug (the object) with clinical 
consequences.  
1.6.1. Altered bioavailability  
This occurs when the amount of the object drug reaching the systemic circulation is 
affected by a perpetrator drug. For orally administered drugs this occurs when absorption or 
first-pass metabolism is altered. Drugs with low oral bioavailability are often affected while 
those with high bioavailability are seldom affected. For example, alendronate and dabigatran 
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have low oral bioavailability. Alendronate co-administration with calcium decreases 
bioavailability and can result in no alendronate being absorbed. Conversely, dabigatran co-
administration with verapamil increases bioavailability and can result in an increased risk of 
bleeding.  
1.6.2. Altered clearance 
This occurs when the metabolism or excretion of the object drug is affected by a 
perpetrator drug. Object drugs with a narrow therapeutic index (see Table 2) are particularly 
vulnerable, as modest changes in concentration may be clinically important. Perpetrator drugs 
known to strongly affect drug metabolism (see Table 3) are more likely to cause large 
concentration changes and hence clinical consequences.
24
 Recognising these potential 
perpetrators of pharmacokinetic drug-drug interactions is important.   
1.6.3. Metabolism  
Changes in drug metabolism are the most important causes of unexpected drug 
interactions. These occur by changing drug clearance or oral bioavailability. There are several 
enzyme families involved in drug metabolism, and the cytochrome P450 (CYP) enzyme 
family is the most important (see Table 3).  
Inhibition of a cytochrome P450 enzyme increases the concentration of some drugs by 
decreasing their metabolism. For example, clarithromycin is a strong inhibitor of CYP3A-
catalysed simvastatin metabolism, thus increasing the risk of myopathy.
25
 Drug inhibition of 
cytochrome P450 enzymes is also used therapeutically. For example, ritonavir, a strong 
inhibitor of CYP3A, reduces the metabolism of other protease inhibitors thus increasing their 
effectiveness in treating HIV (so-called ‘ritonavir-boosted' regimens).26  
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Induction of a cytochrome P450 enzyme decreases the concentration of some drugs by 
increasing their metabolism. For example, carbamazepine is a strong inducer of CYP3A that 
increases the metabolism of the combined oral contraceptive, thus increasing the risk of 
unwanted pregnancy.
27
  
1.6.4. Prodrugs  
Some drugs rely on cytochrome P450 enzymes for conversion to their active form. As 
this is usually dependent on a single enzyme pathway, prodrugs are particularly vulnerable to 
changes in metabolism. Inhibition of conversion from prodrug to active drug may lead to 
inadequate concentrations of the active drug and therapeutic failure. For example, tamoxifen 
is metabolized by CYP2D6 to its active form endoxifen, and concomitant therapy with the 
strong CYP2D6 inhibitor paroxetine has been associated with increased mortality in breast 
cancer.
28
  
1.6.5. Excretion 
Some drugs are excreted from the body unchanged in the active form, usually in the 
urine or via the biliary tract in the feces. Changes in renal drug clearance may occur due to 
effects on renal tubular function or urine pH. For example, probenecid reduces the renal 
clearance of anionic drugs such as methotrexate and penicillin.   
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Table 2: Examples of drug classes containing several narrow therapeutic indexes 
(object) drugs 
Drug class  Examples 
Antiarrhythmics Amiodarone  
Anticoagulants  Warfarin  
Antiepileptics  Phenytoin  
Antineoplastics  Sunitinib  
Aminoglycoside antibiotics  
 
Gentamicin  
Immunosuppressants Tacrolimus  
The therapeutic index is often easier to recognize than define, as the vulnerability of the 
patient affects the dose-response relationship. A clinical question which is useful to identify a 
narrow therapeutic index drug is: would doubling or halving the dose of this drug have a 
major effect on this patient? 
 
 
Table 3: Important perpetrators of cytochrome P450 drug-drug interactions
24 
Enzymes  Inhibitors*  Inducers  
CYP1A2  
ciprofloxacin, fluvoxamine, 
ethinyloestradiol, interferon alfa-2b  
Phenytoin, rifampicin  
CYP2C9  fluconazole  Carbamazepine, rifampicin  
CYP2C19  
fluconazole, fluvoxamine, 
ticlopidine, fluoxetine, 
clarithromycin, voriconazole, 
Lopinavir/ritonavir, rifampicin, St 
John’s wort  
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moclobemide  
CYP2D6  
bupropion, fluoxetine, paroxetine, 
perhexiline, cinacalcet, doxepin, 
duloxetine, flecainide, 
moclobemide, quinine, terbinafine  
 
CYP3A  
macrolides e.g. erythromycin, 
clarithromycin  
azole antifungals e.g. 
voriconazole, itraconazole, 
ketoconazole, fluconazole, 
posaconazole  
protease inhibitors e.g. indinavir, 
ritonavir, saquinavir, atazanavir, 
fosamprenavir  
non-dihydropyridine calcium 
channel blockers e.g. diltiazem, 
verapamil  
grapefruit juice, aprepitant, 
cimetidine, ciprofloxacin, 
cyclosporin, fluvoxamine, imatinib  
Carbamazepine, modafinil, 
phenytoin, phenobarbitone, rifabutin, 
rifampicin, St John’s wort  
* Bold font indicates very strong inhibitors 
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1.6.6. Altered distribution 
This occurs when the concentration of drug at the site of action is changed without 
necessarily altering its circulating concentration. This is particularly an issue for drugs with 
intracellular or central nervous system targets. Some drugs cause significant changes in the 
cell membrane transport of other drugs. For example, verapamil inhibits efflux transporters 
(e.g. P-glycoprotein) increasing the concentrations of substrates such as digoxin and 
cyclosporin. Probenecid inhibits anion transporters (e.g. OAT-1) increasing the 
concentrations of substrates such as methotrexate and penicillins. Drug interactions involving 
transport are less well understood than drug interactions involving metabolism. 
1.7. PHARMACODYNAMIC DRUG-DRUG INTERACTIONS 
Pharmacodynamics is ‘what the drug does to the body’. These interactions occur 
between drugs with additive or opposing effects. The brain is the organ most commonly 
compromised by pharmacodynamic interactions. 
Pharmacodynamic interactions between drugs with additive effects may be 
intentional, for example when combining antihypertensives, or unintentional, for example, 
serotonin syndrome caused by adding tramadol to a selective serotonin reuptake inhibitor 
(SSRI). Conversely, combining drugs with opposing effects can result in loss of drug effect, 
for example, reduced bronchodilation by a beta2 agonist prescribed with a non-selective beta 
blocker.
29
 
Considering drug effects by the organ is a useful way to recognize pharmacodynamic 
interactions. Ask yourself – might any of these drugs affect the same organ (for example the 
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brain)? This approach allows you to consider interactions between drugs with different modes 
of action, for example, an anticholinergic and a benzodiazepine.
30
 
1.8. HOW TO AVOID UNWANTED DRUG-DRUG INTERACTIONS IN 
CLINICAL PRACTICE 
Ensure you have a full drug history including over-the-counter and herbal products. 
Pharmacodynamic drug-drug interactions can be anticipated based on knowledge of the 
clinical effects of the drugs involved. The better your pharmacological knowledge, the easier 
it is! Prescribe few drugs and know them well. 
Pharmacokinetic drug-drug interactions are more difficult to anticipate since they are 
not predictable from the clinical effects of the drugs involved. Recognition of drugs that have 
a narrow therapeutic index (Table 2) and the major perpetrators of pharmacokinetic 
interactions (Table 3) will help identify most of these. 
We use five ‘rules' to manage potential drug-drug interactions in clinical practice: 
1. Any interactions between existing drugs in a given patient have already occurred. 
Hence they are part of the differential diagnosis.  
2. Knowledge of the pharmacological effects of drugs and of patient physiology together 
allows recognition of potential pharmacodynamic drug-drug interactions. 
3. Drugs with a narrow therapeutic index are particularly susceptible to pharmacokinetic 
drug-drug interactions (Table 2). 
4. A small number of drugs are important ‘perpetrators' of pharmacokinetic drug-drug 
interactions (Table 3). 
5. Starting or stopping a drug is a prescribing decision that may cause a drug interaction. 
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Monitoring patients for drug toxicity or loss of efficacy are part of routine care. Checking for 
changes in symptoms, biomarkers of effect or drug concentrations soon after prescription 
changes helps identify drug interactions early and can reduce harm. 
1.9. CLINICAL RESOURCES FOR DRUG-DRUG INTERACTIONS 
A number of resources are available to help clinicians with drug-drug interactions: 
 Individual drug monographs in formularies, such as the Australian Medicines 
Handbook, are a useful starting point for learning about new drugs 
 Tables listing the major perpetrators of pharmacokinetic drug-drug interactions are 
available in the Australian Medicines Handbook or online (www.pkis.org) 
 Prescribing and dispensing software mostly generates alerts from tables of 
information about drug pairs. The time involved and the amount of irrelevant 
information retrieved may cause ‘alert fatigue’ and limit their clinical utility.31 
 Drug information services have access to reference information such as Stockley’s 
Drug Interactions and Micromedex. 
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2. LITERATURE REVIEW 
Rakesh Romday et al., (2016)
6
 conducted study on the new guidelines issued by the 
joint national committee on prevention, detection, evaluation, and treatment of high blood 
pressure (JNC-8) emphasize that aggressive blood pressure (BP) control is essential to 
reducing morbidity and mortality. Patient non-adherence is a serious obstacle to the effective 
treatment of many acute and chronic disorders. Successful treatment and outcome of a 
chronic disease such as hypertension depend on many factors, including resources (e.g., 
funds, space, and people), avoidance of serious adverse events, patient adherence with 
treatment plans, and the availability of effective therapies. The aim of this study is to assess 
the antihypertensive drug prescription patterns and adherence to a joint national committee 
(JNC-8) hypertension (HT) treatment recommendations among hypertensive patients 
attending a tertiary care teaching hospital. An observational and cross-sectional prospective 
prescription audit study was carried over a period of 1 year in ambulatory patients attending 
medicine OPD. A total of 500 prescriptions prescribed to diagnose HT were analyzed. Drug 
prescription patterns and their adherence to JNC-8 report were assessed. Out of 500 patients, 
299 (59.8%) were male and 201 (40.2%) were female. Mean age of male and female patients 
were found to be 57.68±15.32 and 61.29±12.65 years respectively. As per the present study, 
most of the physicians prescribed a single drug (monotherapy, 34.6%) to control BP followed 
by two-drug combination (18.4%), three-drug combination (11.8%) and four-drug 
combination (3%). Two drugs regimen was prescribed for 18.4% of the hypertensive patients. 
Angiotensin receptor blocker + diuretic combination (4.4%) was mostly used in two-drug 
combination therapy followed by Angiotensin receptor blockers + Diuretics (3.6%) and 
Calcium channel blocker + ACEIs combination (2.6%). No combination of ACEIs + ARBs 
was prescribed in any prescription. The overall rate of adherence was 16.5 % (Pre-
hypertension); 87.90% (Stage 1 hypertension); and 68.20% (Stage 2 hypertension). In 
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conclusion, the present study demonstrated that physicians are not completely adhering to 
standard guidelines while treating hypertension with comorbid conditions. 
Barry et al., (2002)
8
 conducted a study on drug interactions are a frequent cause of 
adverse drug events and these might be avoided by computer alerts to physicians or 
pharmacists. We evaluated the frequency of potential drug-drug interactions in patients 
receiving medications commonly used for hypertension. Patients more than 30 years of age 
with hypertension who were receiving Medicaid and who were enrolled in the Iowa 
Pharmaceutical Case Management (PCM) program were evaluated. All prescription claims 
for patients were obtained on their date of eligibility. A drug interaction database was 
developed to examine potential drug interactions in each patient’s regimen. There were 1574 
patients who received a drug typically used for hypertension. Depending on age and sex, 23% 
to 48% of patients had a potential interaction of high significance and 55% to 84% had at 
least one potential interaction. Both increasing age (P  .0007, odds ratio [OR] 1.012 
[1.005,1.019]) and a number of drugs (P .0001, OR 1.120 [1.092,1.150]) were significantly 
associated with the potential for a highly significant drug interaction in the univariable 
models. Female sex was not significant (P  .56, OR 1.074 [0.845,1.364]). The multivariable 
model found that there was a significant interaction between age and the number of drugs in 
the regimen (P  .0001). Conclusions: This study found a very high frequency of potential 
drug interactions with agents typically used for hypertension. Because of the large volume of 
potential interactions, these data raise the concern that any attempt to provide physicians and 
pharmacists with computer alerts about these interactions will result in alerts for the vast 
majority of patients. 
Javedh Shareef et al., (2017)
9
 conducted study on drug-drug interaction (DDI) 
occurs when two or more drugs are simultaneously administered, where the effect of one 
drug is altered by the concomitant use of another drug. The prospective observational study 
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aimed to assess the potential drug-drug interactions (pDDIs) in general medicine department 
of a multispecialty teaching hospital. Data of all the patients admitted to the general medicine 
department was collected and analyzed for drug-drug interactions by using drug information 
resources such as "Thomson Reuters MICROMEDEX® 2.0 DRUGDEX and drugs.com. A 
total of 150 case records were reviewed, 116 (77.33%) cases were identified with 273 
potential drug-drug interactions during the study period. It was observed that out of the 273 
DDIs identified, majority 68.13% of the interactions were moderate in severity followed by 
19.78% were minor and 12.08% were major. The categorization of onset of drug-drug 
interactions revealed that 53.47% were categorized as ‘not specified' and the documentation 
status of drug-drug interactions showed that 56.77% were ‘fair' in nature. The study 
highlights the need of regular monitoring of drug therapy in identifying and preventing the 
medications that have the potential to cause drug-drug interactions thereby minimizing the 
undesirable outcomes in drug therapy and improving the quality of care. 
Erna Yanti et al., (2017)
10
 conducted a study on patients with hypertension often 
suffer from other comorbidities, resulting in prescriptions of multiple drugs to treat the 
conditions. Multiple drug treatment is potentially associated with drug interactions. This aim 
of the study was to assess potential drug interactions in hypertensive patients in Liwa District 
Hospital. The design of the study was cross-sectional. The prescriptions for in-patients with 
essential hypertension in the Internal Medicine Unit in Liwa District Hospital during April-
December 2012 were collected. Potential drug interactions were analyzed with the Drug 
Interaction Facts version 4.0, and classified into minor, significant, and serious. A total of 60 
hypertensive patients were included. They have prescribed 265 prescriptions, with a median 
total of 6 (range 1-21) drugs prescribed per prescription. There were 1616 potential drug 
interactions, with 6 (1-31) potential interactions per prescription. Most interactions (75.6%) 
were classified as significant. Serious potential interactions were most common in the 
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combinations of diltiazem-amlodipine and spironolactone-potassium chloride, while 
significant potential interaction may occur most often with the combinations of calcium 
chloride-amlodipine and bisoprolol-amlodipine. Numerous potential drug interactions might 
occur in hypertensive patients, and most interactions were significant in severity. The largest 
proportion of the interactions occurred between antihypertensive agents and other drugs. 
Atika Wahyu Puspitasari et al., (2017)
1
 conducted a study on hypertension is a 
common disease around the world. Depending on the severity or the presence of other 
diseases, whether related or unrelated, additional drug therapy may be required to optimize 
treatment and to reduce the side effects of drugs. The use of drugs in large amounts may 
increase the risk of drug interactions. The purpose of this research was to evaluate the 
characteristics of hypertension patients, prescriptions, and potential drug interactions in 
hypertensive patients in the Sukmajaya Community Health Center from June to November 
2015. This research used a descriptive analytic method and the data were retrospectively 
obtained. The results were based on the analysis of 350 prescriptions of female (67.43%) and 
male (32.57%) patients, with the highest prevalence of hypertension occurring at the age of 
≥55 years. Potential drug interactions were analyzed using Micromedex. The most frequent 
potential interaction resulted from the combined use of captopril and non-steroidal anti-
inflammatory drugs. The most frequent mechanism of drug interaction was pharmacokinetics 
(51.06%). The chi-square test results showed a significant relationship between the number of 
prescribed drugs and potential interactions at a probability value of 0.0001 and an odds ratio 
of 5.940 (15.588-2.263). With respect to the interaction mechanism, pharmacokinetic 
(51.06%) was the most frequent and 61.70% of potential cases involved a moderate 
interaction risk. 
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Pankti S. Patel et al., (2014)
11
 conducted a study on to evaluate prevalence, types, 
and severity of potential adverse drug‑drug interaction in medicine out‑patient department. A 
single‑point, prospective, and observational study was carried out in medicine OPD. The 
study began after obtaining approval Institutional Ethics Committee. Data were collected and 
potential drug‑drug interactions (pDDIs) were identified using Medscape drug interaction 
checker and were analyzed. A total of 350 prescriptions with a mean age of 52.45 ± 14.49 
years were collected over a period of 5 months. A total of 2066 pDDIs were recorded with a 
mean of 5.90 ± 6.0. The prevalence of pDDI was 83.42%. Aspirin was the most frequently 
prescribed drug in 185 (10.15%) out of a total of 1821 drugs It was also the most frequent 
drug implicated in pDDI i.e. in 48.16%. The most common pDDI identified was metoprolol 
with aspirin in 126 (6.09%). Mechanism of interactions was pharmacokinetic in 553 
(26.76%), pharmacodynamic in 1424 (68.92%) and 89 (4.30%) having an unknown 
mechanism. Out of all interactions, 76 (3.67%) were serious, 1516 (73.37%) significant, and 
474 (22.94%) were minor interaction. Age of the patients (r = 0.327, P = 0.0001) and number 
of drugs prescribed (r = 0.714, P = 0.0001) are significantly correlated with drug interactions. 
Aspirin is the most common drug interacting. The use of electronic decision support tools, 
continuing education, and vigilance on the part of prescribers toward drug selection may 
decrease the problem of pDDIs. 
Sagar Pamu et al., (2017)
12
 conducted a study on a retrospective survey of potential 
drug-drug interactions. To analyze the risk which it was associated with drug interaction in 
hypertensive patients. To identify the drug that most commonly implanted in Drug-Drug 
interactions and to recognize the antihypertensive drug mostly interacting with another drug. 
The study was done in the general medicine ward of secondary care hospital in Secunderabad 
for a period of 9 months for the detection of drug interactions in prescriptions containing anti-
hypertensive drugs which were prescribed. The study involves the following steps, a 
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collection of prescription (schedule method). Recording of prescription details. Analyzing 
prescriptions and finding the individual drug interaction. A total of 151 prescriptions were 
collected on the basis of inclusion (age, sex, other diseases like DM, etc) and exclusion 
(pregnant) criteria and analyzed for drug-drug interactions. It is shown that 20% (31) of 
prescriptions having drug-drug interactions in hypertensive patients. From this amlodipine is 
interacting with 8 drugs, furosemide with 5 drugs, atenolol with 6 drugs, enalapril with 5 
drugs, ramipril with 3, digoxin with 2, nifedipine with 2, nebivolol with 2. From this study, 
we concluded that amlodipine and digoxin, were commonly interacting with more no drugs 
and nifedipine and nebivolol are least. Those 31 drug interactions case sheets were 
individually again studied and found that there were 26 different drug combinations causing 
interactions. Some drugs were interacting with more than one drug in the list. The severity of 
these 26 different interactions was founded that there were 4 major interaction and 15 
moderate interactions. From this individualized study, amlodipine was found to be the most 
interacting drug and combination which repeated mostly was amlodipine and atenolol, 
causing a reduction in heart rate, cardiac contractility, and hypotension. It is concluded that 
the drug interaction cases constitute 20% of the 151 hypertensive prescriptions. In future 
these drug interactions effectively overcome by dose adjustment, monitor blood pressure, use 
combination with caution, clinically monitoring the patient.  
Nitin Kothari et al., (2014)
7
 conducted a study on drug-drug interactions(DDIs) are 
significant but avoidable causes of iatrogenic morbidity and hospital admission. To detect 
potential drug-drug interactions among medications received by hypertensive patients. 
Patients of both sex and all adult age groups, who were attending medicine outpatient 
department (OPD) of a tertiary care teaching rural hospital since last six months and were 
being prescribed antihypertensive drug/s for essential hypertension, were selected for the 
study. Hypertensive patient with co-morbidities diabetes mellitus, ischemic heart diseases, 
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congestive heart failure, and chronic renal diseases were also included in the study. Potential 
drug-drug interactions were checked with Medscape drug interaction software. With the help 
of Medscape drug interaction software, 71.50% prescriptions were identified having at least 
one drug-drug interaction. Total 918 DDIs were found in between 58 drug pairs. 55.23% 
DDIs were pharmacodynamic, 4.79% pharmacokinetic type of DDIs. 32.24% DDIs were 
found affecting the serum potassium level. 95.42% DDIs were found the significant type of 
DDIs. Drug-drug interaction between atenolol & amlodipine was the most common DDI 
(136) followed by metoprolol and amlodipine (88) in this study. Atenolol and amlodipine      
(25.92%) were the most common drugs to cause DDIs in our study. We detected a significant 
number of drug-drug interaction in hypertensive patients. These interactions were between 
antihypertensive agents or between hypertensive and drug for the co-morbid condition.  
Ansha Subramanian et al., (2018)
13
 conducted a study on drug-drug interactions 
(DDIs) are one of the major but preventable causes of adverse drug reaction. Study of 
prevalence and prediction of DDIs will make the physician easier to provide better patient 
care and mitigate patient’s harm. Hence, the study was planned to evaluate the potential DDIs 
among medication prescribed to hypertensive patients in our hospital. A prospective, cross‑
sectional study was conducted among the hypertensive patients in medicine 
(outpatient/inpatient) department over the period of three months in a tertiary care hospital. 
Adult hypertensive patients of either sex with comorbidities were included in the study. The 
prescriptions were collected and analyzed for DDI using Medscape interaction checker. Data 
were analyzed using SPSS (version 16.0) software and expressed in percentage. Pearson’s 
correlation and regression analysis were done. Among 125 patients, 48% were exposed to at 
least one DDI. Totally 123 DDI were identified and the majority of them were significant 
(85.36%). No serious interactions were identified. Pharmacodynamic and pharmacokinetic 
drug interactions were found to be 37.39% and 28.76%, respectively. Logistic regression 
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analysis showed advanced male gender and polypharmacy was associated with increased risk 
of DDI. About 51 interacting pairs of DDI were identified and most frequently occurring pair 
was amlodipine with atenolol. Aspirin was found to have commonly involved in DDI with 
enalapril, atenolol, frusemide, spironolactone, carvedilol, and metoprolol. The study 
highlighted that patients with hypertension are particularly vulnerable to DDI. The 
comorbidities, advanced age, and polypharmacy are the important factors associated with the 
occurrence of DDI. 
Joseph Olusesan Fadare et al., (2016)
14
 conducted a study on drug-drug interactions 
remain a major cause of adverse drug reactions with great consequences such as increased 
morbidity and increased healthcare cost. In elderly patients with systemic hypertension, there 
is a tendency for them to be prescribed multiple medications and this may expose them to 
some drug-drug interactions (DDIs) especially in the context of physiological changes of 
aging. The objective of this study was to evaluate potential drug-drug interaction among 
some Nigerian elderly hypertension. A cross-sectional study involving elderly hypertensive 
patients attending the general outpatient clinic of two tertiary healthcare facilities located in 
Ekiti State, South-West Nigeria. The information collected from the patients’ medical records 
included their ages, gender, diagnosis, and list of prescribed anti-hypertensive medications. 
Potential drug-drug interactions were checked for using the Multi-Drug Interaction Checker 
(Medscape Reference) and Epocrates Drug Interaction Checker (San Mateo CA, USA). A 
total of 350 elderly patients attended the clinics during the study period of which 208 (59.4%) 
hypertensive patients were identified and their records used for analysis. The fixed-dose 
combination drug Moduretic® (Amiloride /Hydrochlorothiazide)-25.7% was the most 
commonly prescribed antihypertensive followed by Lisinopril (16.6%), Amlodipine (13.2%) 
and Nifedipine (12.6%). The anti-platelet Acetyl-salicylic acid (ASA) was prescribed for 100 
(48.1%) patients and represented 19.8% of all prescribed medications. A total of 231 
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potential DDIs were found among the patients giving a mean of 1.3 interactions per patient. 
The most common identified drug pairs with potential interactions were ACE inhibitors – 
Amiloride, followed by ACE inhibitors – Hydrochlorothiazide, ACE inhibitors - ASA and 
ARB – Amiloride. Conclusion: Potential drug-drug interactions, though common in this 
study comprised mainly of minor and moderate types. Notwithstanding, physicians need to be 
reminded of the potential for interactions when prescribing for elderly patients. 
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3. AIM AND OBJECTIVES 
3.1 AIM OF WORK 
           To an assessment of potential drug-drug interactions in hypertensive patients in a 
tertiary care hospital. 
 3.2 OBJECTIVES 
 To identify the prevalence of potential drug-drug interactions, in hypertensive 
patients. 
 To pick out the types and severity of PDDIs. 
 To analyses the hazard which it became associated with drug interaction in 
hypertensive patients. 
 To identify the drug that most commonly implanted in drug-drug interactions 
and to understand the antihypertensive drug mainly interacting with different 
drugs. 
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3.3 PLAN OF WORK 
    The proposed work is designed as mentioned below: 
Phase I 
• Literature survey. 
• Obtaining institutional ethical committee clearance. 
• Obtaining consent from hospital authorities. 
• Designing data entry form, patient consent forms. 
Phase II 
• Collection of data’s from hospitalized hypertensive patients. 
Phase III 
• To identify the prevalence of potential drug-drug interactions, in hypertensive 
patients. 
• To pick out the types and severity of PDDIs. 
• To analyses the hazard which it became associated with drug interaction in 
hypertensive patients. 
• To identify the drug that most commonly implanted in drug-drug interactions 
and to understand the antihypertensive drug mainly interacting with different 
drugs. 
• Submission of Report. 
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3.4 METHODOLOGY 
Study design: 
• It is a prospective  observational study 
Study site: 
• The research work was conducted at a tertiary care hospital, Erode, Erode 
district, Tamil Nadu. 
Study period:  
• 8 Months 
   Inclusion criteria: 
• Hospitalized hypertensive patients  
• Age companies >18 years. 
• Prescriptions with  or 2 more drugs prescribed throughout the hospitalization 
had been only decided on for the study. 
Exclusion criteria: 
• Outpatients. 
• Alternative system (Ayurveda, Siddha) of medicine. 
• Age group <18 years. 
• Prescription with much less than 2 drugs prescribed. 
Source of data: 
The data were collected from case sheets of hospitalized patients and direct patient 
interview with hypertensive patients. 
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3.5  WORK METHODOLOGY 
 All the hospitalized patients under the overall medicine department have been 
reviewed on each day basis from the day of admission till the day of discharge and 
those who met the observe standards have been enrolled within the study. all the 
applicable and vital information of the patients which includes the demographic data, 
laboratory parameters, and drug therapy details had been accrued from the patient 
case notes and via interviewing patient bystanders and healthcare experts if essential. 
 The demographic details consist of age, gender, the reason for admission, past 
medical records, medication records, co-morbidities and any records of hypersensitive 
reactions. The recording of laboratory parameters consists of hematology, 
biochemistry and any other tests that were executed at some stage in their hospital 
stay. The drug therapy information which include dose, duration, frequency, route, 
time of administration and concomitant drug have been also stated. all the collected 
data have been documented in the certainly designed data collection form designed as 
per the need of the study. The patient drug therapy was reviewed each day and 
assessed for drug interactions checker by way of the use of Micromedex®- 2.7 
software. 
 The diagnosed potential drug-drug interactions had been categorized into 3 groups 
based on severity, namely, minor, moderate, major and types respectively.  
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4. RESULTS 
Table 1: Distribution of drug-drug interactions in hypertensive patients 
S. No Total number of cases 
collected 
Total number of cases with 
potential drug-drug 
interactions 
Total number of 
potential drug-drug 
interactions 
1. 480 396 (82.50%) 1160 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Distribution of drug-drug interactions in hypertensive patients 
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Table 2: Gender wise distribution of drug- drug interactions 
S. No Gender Frequency (n = 396) Percentage (%) 
1. Male 141 35.60% 
2. Female 255 64.39% 
 
 
 
 
 
 
 
 
 
 
Figure 2: Gender wise distribution of drug- drug interactions 
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Table 3: Age wise distribution 
S. No. Age (in years) Frequency(n=396) Percentage (%) 
1. 18-30 15 03.78% 
2. 31-45 42  10.60% 
3. 46-59 99  25.00% 
4. 60-70 177 44.69% 
5. Above 70 63 15.90% 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Age wise distribution 
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Table 4: Number of hospital stay 
S. No 
No. of Hospital 
Stay (in days) 
Frequency (n=396) Percentage (%) 
1. <3 85 21.46% 
2. 4 – 6 272 68.68% 
3. >7 39 09.84% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Number of hospital stay 
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Table 5: Number of prescribed drugs per day 
S. No Number of drugs 
prescribed/day 
Frequency (n=396) Percentage (%) 
1. <4 35 8.83% 
2. 5-6 166 41.91% 
3. >7 195 49.24% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Number of prescribed drugs per day 
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Table 6: Distribution of co-morbidities diseases in hypertensive patients 
 
Co-morbidities disease 
 
 
Total number of patients 
with PDDIs 
(n=396) 
 
Percentage (%)  
 
Hypertension  
 
 
162 
 
40.90 
 
Hypertension + Diabetes 
 
 
68 
 
17.17 
 
Hypertension + 
Cardiovascular disease 
 
 
41 
 
10.35 
 
Hypertension +  
Asthma 
 
 
36 
 
9.09 
 
Hypertension + kidney 
disease 
 
 
12 
 
3.03 
 
 Pre-eclampsia 
 
 
18 
 
4.54 
 
Hypertension + Diabetes + 
cardiovascular disease 
 
 
39 
 
9.84 
 
Hypertension + Diabetes + 
Asthma 
 
 
8 
 
2.02 
 
pre-eclampsia+ Diabetes 
 
 
12 
 
3.03 
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Figure 6: Distribution of co-morbidities diseases in hypertensive patients 
 
Table 7: Highest prescribed single antihypertensive drugs 
Drugs prescribed Number of patients drugs received 
Metoprolol 41 
Amlodipine  175 
Telmisartan  45 
Atenolol  38 
Olmesartan  68 
Losartan  33 
Enalapril  31 
Ramipril  28 
Propranolol  18 
Furosemide  45 
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Table 8: Highest prescribed combination of 2 antihypertensive drugs 
Drugs prescribed Number of patients drugs received 
Asprin + clopidogrel 75 
Amlodipine + simvastatin 108 
Digoxin+bisoprolol 45 
Captopril + metformin 38 
Hydrochlorothiazide + captopril 17 
Enalapril + furosemide 21 
Losartan+captopril 31 
Spironolactone + potassiumchloride 95 
Atenolol + metformin 48 
Aspirin + enalapril 39 
Nifedipine  + aminophylline 45 
Captopril + metformin 65 
Hydrochlorothiazide + captopril 48 
Amlodipine + simvastatin 68 
Glibenclamide + antacid 38 
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4 
3 
1 
1 
1 
Telmisartan+Hydrochlorot
hiazide+ Metoprolol
Furosemide + Amlodipine
+ Atenolol
Metoprolol + Amlodipine
+ Enalapril
Losartan + Amlodipine +
Hydrochlorothiazide
Telmisartan + Amlodipine
+ Metoprolol
Diltiazem+amlodipine 43 
 
Table 9: Prescribed combination of 3 antihypertensive drugs 
Drugs prescribed Number of patients drugs received 
Telmisartan+Hydrochlorothiazide+ 
Metoprolol 
 
4 
Furosemide + Amlodipine + Atenolol 
 
3 
Metoprolol + Amlodipine + Enalapril 
 
1 
Losartan + Amlodipine + 
Hydrochlorothiazide 
 
1 
Telmisartan + Amlodipine + Metoprolol 
 
1 
 
 
 
 
 
 
 
 
 
Figure 7: Prescribed combination of 3 antihypertensive drugs 
An assessment of potential drug-drug interactions in hypertensive patients in a tertiary care 
hospital 
 
Department of Pharmacy Practice                   38            J.K.K. Nattraja College of Pharmacy 
 
Table 10: Highest potential drug-drug interaction combinations in hypertensive patients 
 
 
 
PDDIs Combination Types Severity 
Frequency 
(n=1160) 
Percentage 
(%) 
Asprin + clopidogrel 
PD Major 325 28.01 
Amlodipine + simvastatin 
Unknown Major 172 14.82 
Digoxin+bisoprolol 
PD Moderate 85 7.32 
Captopril + metformin 
PD Moderate 38 3.27 
Hydrochlorothiazide + 
captopril  
PD Moderate 41 3.53 
Enalapril + furosemide 
PD Moderate 67 5.77 
Losartan+captopril 
PK Major 47 4.05 
Spironolactone+potassium 
chloride  
PK Major 38 3.27 
Atenolol + metformin 
PK Moderate 66 5.68 
Aspirin + enalapril 
PD Moderate 39 3.36 
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Figure 8: Highest potential drug-drug interaction combinations in hypertensive patients 
 
Table 11: Anticipated effect, M.O.A, Clinical Management for common potential drug-
drug interactions in cardiology 
PDDIs combination 
Mechanism of 
action 
Anticipated effects Remedy 
Aspirin + clopidogrel 
 
Additive Effect 
 
Increased risk of 
bleeding. 
Monitor for blood 
counts if co-
administration is 
needed 
Amlodipine + simvastatin Unknown 
Increased 
simvastatin 
exposure and 
increased risk of 
myopathy, 
including 
rhabdomyolysis. 
Dose adjustment 
required. 
Simvastatin should 
not exceed 20 
mg/day 
Digoxin + bisoprolol additive effects on Increased risk of 
Monitor heart rate 
and PR interval 
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AV node 
conduction 
bradycardia and 
possible digitalis 
glycoside toxicity. 
Captopril + metformin Unknown 
Increased risk of 
hypoglycemia. 
Monitor glucose 
level 
Hydrochlorothiazide + 
captopril 
Vasodilation and 
relative 
intravascular 
volume depletion 
Reduction of blood 
pressure 
Decreasing or 
discontinuing the 
diuretic or 
increasing salt 
intake may 
minimize the risk of 
hypotensive effects. 
Enalapril + furosemide Synergistic Effect  
Result in postural 
hypotension 
Discontinue the 
diuretic 2 or 3 days 
prior to ACEI 
Losartan+captopril 
Dual blockade of 
the renin-
angiotensin-
aldosterone system 
Increased risk of 
adverse events (ie, 
hypotension, 
syncope, 
hyperkalemia, 
changes in renal 
function, acute 
renal failure). 
Monitor blood 
pressure, renal 
function, and 
electrolytes 
Spironolactone+potassium 
chloride  
Decreased renal 
clearance 
May result in 
hyperkalemia. 
Discontinue 
potassium 
supplementations 
when spironolactone 
therapy is initiated. 
Monitor serum 
potassium closely. 
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32.84% 
42.75% 
24.39% 
Types of Prevalence of PDDIs 
Major
Moderate
Minor
Atenolol + metformin 
Altered glucose 
metabolism and 
beta blockade 
May result in 
hypoglycemia or 
hyperglycemia 
Monitor for blood 
glucose level. 
Aspirin + enalapril Antagonistic Effect 
Decreased 
effectiveness of 
enalapril 
Weigh benefit and 
risk. 
 
Table12: Types of Prevalence of PDDIs 
 
S. NO 
 
Severity of PDDIs 
 
Frequency (n=1160) 
 
Percentage (%) 
1. Major 
 
381 
 
32.84% 
2. Moderate 
 
496 
 
42.75% 
3. Minor 
 
283 
 
24.39% 
 
 
 
 
 
 
 
 
 
Figure 9: Types of prevalence of potential drug-drug interactions 
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33.79% 
53.79% 
5.94% 
6.29% 
PK
PD
PK+PD
Unknown
Table 13: Classification of Types of PDDIs 
 
 
Types 
 
Frequency (n=360) 
 
Interacting Pairs 
(n=96) 
 
 
Total Number of Interactions 
(n=1160) 
 
Percentage 
(%) 
PK 392 33.79% 32 
  PD                         626  53.96% 47 
PK + PD 69 05.94% 6 
Unknown 73 06.29% 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Types of potential drug-drug interactions 
 
An assessment of potential drug-drug interactions in hypertensive patients in a tertiary care 
hospital 
 
Department of Pharmacy Practice                   43            J.K.K. Nattraja College of Pharmacy 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
13.01% 
20.15% 
50.51% 
16.32% 
Classification of PK Interactions 
Percentage (%)
Table 14: Classification of Pharmacokinetics interactions 
 
Types 
Total number of 
occurrences(n =392) 
 
Percentage (%) 
Absorption 51 13.01% 
Distribution 79 20.15% 
Metabolism 198  50.51% 
Excretion 64  16.32% 
Distribution  
+ 
 Excretion 
- 
 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Classification of Pharmacokinetics interactions 
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29.55% 
10.86% 51.75% 
7.82% 
Classification of PD Interactions 
Antagonism
Synergism
Additive
Antagonism +  Additive
Table 15: Classification of PD Interactions 
Types 
Total number of 
occurrences (n =626) 
Percentage (%) 
Antagonism 185 29.55% 
Synergism 68 10.86% 
Additive 324 51.75% 
Antagonism +  Additive 49 7.82% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Classification of Pharmacodynamics interactions 
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5. DISCUSSION 
Drug interactions are a major area of challenge in recent times for the effective 
management of patient contamination. It is able to create a great health hazard to the patients 
when the risk-benefit ratio of combining interacting drugs is not as it should be envisioned. It 
has already been approximated that the impact of drug interactions can range from any minor 
morbidity to fatal effects. The study of drug-drug, interactions and of genetic factors affecting 
pharmacokinetics and pharmacodynamics is expected to improve drug protection and could 
allow individualized drug therapy. 
In our study identified a total of 480 hypertensive patients were admitted to the 
hospital during the study period. Among these, 480 hypertensive patients, 396 (82.50%) had 
found to be PDDIs, 1160 PDDIs were found in 396 hypertensive patients (Table 1). Out of 
which 255 (64.39%) female patients found to be higher PDDIs, compared to males 141 
(35.60%), which are similar to the study conducted by Puspitasari et al.,
1
 (Table 2). wherein 
it was also reported that the prevalence of hypertension is higher in female patients than in 
male patients
2
. Female patients are more prone to hypertension than male patients based on 
their etiology and pathophysiology. As an example, hypertension due to renal artery stenosis 
is more common in females than males. Other factors that cause hypertension in females are 
the use of oral contraceptives, pre-eclampsia, and vasculitis (inflammation of blood vessels)
3
. 
Our studies revealed that majority of the patients were found to be age group of 60-70 
years, 177 (44.69%) (Table 3). A study conducted by Kameswaran R et al.,
4
 reported that 
incidences of PDDIs were found to be higher in the age group of 60-70 years in cardiac [159 
(44.16%)] patients. Older people were at high risk of developing an ADR due to pDDIs for 
several reasons. They are likely to have higher comorbidities and thus take several 
prescriptions and over the counter drugs. As people get older, the liver loses the ability to 
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metabolize drugs. Also, older people are more than twice as susceptible to ADRs as younger 
people. As people age, the amount of water in the body decreases and the amount of fat tissue 
relative to water, increases. Also, as people age, the kidneys are less able to excrete drugs into 
the urine, and the liver is less able to metabolize many drugs. 
The study revealed that 272 (68.68%) of cases reported that a number of hospital stay 
was between 4-6 days. (Table 4) Kameswaran R et al.,
4
 conducted a study which showed that 
the majority of the cases, the number of hospital stay were between 4-6 days. The likelihood 
of getting the multiple drugs increases with the increased length of hospital stay which in turn 
will increase the likelihood of PDDIs. 
In our study shows that 195 (49.24%) hypertensive patients were prescribed with 
more than 7 drugs (Table 5). The study conducted by Puspitasari et al.,
1
 which have shown  
57.14% cases have been reported as the prescribing greater than 4. Types and combinations 
of prescribed antihypertension and the most prescribed drug for single prescriptions was 
amlodipine at Sukmajaya Community Health Center. Amlodipine has been shown to be a 
well-tolerated antihypertensive drug, especially in elderly patients. Amlodipine tolerability 
has also been shown to be good or excellent in most patients. This is because amlodipine is 
slowly absorbed, and the side effects of vasodilation tend to be smaller than other CCB-group 
drugs. Amlodipine also has a low rate of metabolism in the liver and a longer half-life than 
other drugs, allowing effective blood pressure control with once-daily dosing.
5
 
The study revealed that the highest number of diseases and co-morbid conditions were 
hypertension alone were 162(40.90%), hypertension + diabetes were 68 (17.17%), and 
Hypertension + Cardiovascular diseases were 41 (10.35%), the most co-morbidities disease 
in hypertensive patients, and also the most of the female patients had found to be 
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hypertensive and shown PDDIs (Table 6), a similar study conducted by Romday et al.,
6 
reported that Diabetes mellitus (9.36%, males; 8.96%, females), other cardiovascular diseases 
(14.05%, males; 13.43%, females), acid peptic disease (7.69%, males; 7.46%, females) and 
dyslipidemia (11.70%, males; 13.43%, females) are the most common co-morbidities in 
hypertension patients. 
The study shows that the highest monotherapy drugs prescribed were amlodipine 175, 
followed by telmisartan  65 patients, and olmesartan 58 patients. Combination of 2 drugs 
therapy were  aspirin + clopidogrel 325 patients, followed by amlodipine + simvastatin 172 
patients, and Digoxin+bisoprolol 85 patients, whereas in combination of 3 drugs therapy 
were telmisartan + hydrochlorothiazide +  metoprolol 4 patients, followed by furosemide + 
amlodipine + atenolol 3 patients (Table 7-9). 
The highest most common interacting pair in hypertensive patients had found to be 
between aspirin and clopidogrel; causing major pharmacodynamics interaction, with a 
frequency of 325 (28.01%), followed by amlodipine and simvastatin; causing major severity, 
with a frequency of 172 (14.82%)  (Table 10). The similar to the study conducted by 
Kameswaran R et al.,
4
 in which some of the most common drug interacting pair was aspirin 
and clopidogrel; causing major, pharmacodynamics interaction, with a frequency of 245. 
The prevalence among 1160 PDDIs was 42.75% moderate in severity, 32.84% major 
severity and 24.39% minor severity (Table 12). A similar study was performed by Puspitasari 
et al.,
1 
showed an overall 61.70% were in moderate severity, 29.79% were in major severity 
and 8.51% were in minor severity among the study conducted in hypertensive patients.  
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Out of 396 hypertensive patients, there was 96 interacting pair identified during the 
study. Among 1160 PDDIs, 392  (33.79%) were pharmacokinetic interactions, 626 (53.96%) 
were pharmacodynamic interactions, 69 (05.94%) showing both mechanisms and 73 
(06.29%) were an unknown mechanism (Table 13). Among 392 pharmacokinetic drug 
interactions, 51 (13.01%) were due to absorption, 79 (20.15%) were due to distribution, 198 
(50.51%) were due to metabolism and 64 (16.32%) were due to excretion (Table 14). Among 
626 (53.96%) pharmacodynamic interactions, 68 (10.86%) were synergistic, 185 (29.55%) 
were antagonistic, 324 (51.75%) were additive and 49 (7.82%) with both additive and 
antagonistic effects (Table 15). According to Nitin Kothari et al.,
7 
DDIs was affecting serum 
potassium level (32.24%). DDIs having unknown mechanism were 71 (7.73%) and 
pharmacokinetic DDIs were only 44 (4.79%). Out of 507 pharmacodynamic DDIs, 366 were 
synergistic type while 141 were of an antagonistic type. Majority of synergistic 
pharmacodynamic DDIs, the software found, were between beta-blocker- calcium channel 
blocker (CCB) drug pair and beta blocker- angiotensin receptor blocker (ARB) drug pair. 
Beta-blocker and CCB both increase anti-hypertensive property of each other. 
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6. CONCLUSION 
Our study concluded that the overall incidence of PDDIs was terribly high in 
hypertensive patients. The PDDIs were found to be more in females compared to males, it 
had been found that incidence of pDDIs was associated with older age, polypharmacy and 
accrued lengths of hospital stay. the majority of interactions were pharmacodynamic in 
nature, having a moderate interactions risk. the foremost of the common pDDIs were between 
aspirin and clopidogrel followed by amlodipine and simvastatin.  
 
           Clinical pharmacist ought to have role of regular monitoring of drug therapy in 
identifying and preventing the medications that have the potential to cause drug-drug 
interactions thereby minimizing the undesirable outcomes in drug medical care and 
improving the quality of care. Use of electronic database systems as decision support tools, 
automated prescription alerts to doctors, conducting educational programs and watchful 
towards drug choice will decrease the negative outcomes of pDDIs. therefore a daily review 
of the drug therapy by a clinical pharmacist during a multidisciplinary team might help to 
identify and prevent potential drug-drug interactions particularly in patients with chronic 
disease receiving multiple associated with their co-morbid conditions. These can successively 
help to optimize drug therapy, improve the quality of care and condense the undesirable 
outcomes within the patient drug therapy. 
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DATA ENTRY FORM 
CASE NO: 
PATIENT DETAILS: 
Name:                                                                         IP no: 
Age:                                                                            Dept: 
Sex:                                                                             DOA:  
Wt:                                                                              DOD: 
Ward: 
REASON FOR ADMISSION: 
 
 
 
PAST MEDICAL HISTORY: 
 
 
PAST MEDICATION HISTORY: 
 
 
 
SOCIAL HISTORY: 
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DRUG INTERACTION: 
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Patients Signature                                                        Attending Pharmacist Signature 
PATIENT INFORMATION FORM 
 
Dear participant, 
We are students of J.K.K. NATTRAJA COLLEGE OF PHARMACY, Kumarapalayam. 
Currently conducting a project entitled “An assessment of potential drug-drug interactions 
in hypertensive patients in a tertiary care hospital”. As a part of project, we need to collect 
data including past, social and family history, and history of drug and food allergy, lab 
reports and current medical data. However, no identifiable personal data will be 
disclosed. 
Thank you very much for your kind participation. 
 
CONSENT FORM 
I, _______________________________   have read and understand the above 
information. I have to allow my data to be eflicted for the project work. 
 
 
 
 
 
____________________ ______________ 
Signature of participant                                                                             Date 
Translated by: 
                                                       
 
